A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis

Study Summary

The purpose of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered GLPG3667 once daily for 24 weeks in adult participants with dermatomyositis (DM), followed by an open-label extension (OLE) period until Week 48.

Conditions

Dermatomyositis

Interventions / Drugs

GLPG3667 Placebo

View on ClinicalTrials.gov ↗

Sponsor

GLPG

Galapagos NV

JAK Fibrosis Inflammation

F21/100

Study Details

Enrollment40 participants

Primary Completion—

Lead SponsorGalapagos NV

Data Retrieved2026-04-11 04:14:38.910117+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.